<?xml version="1.0" encoding="UTF-8"?>
<p>As combination therapy with both oseltamivir and H84T could be a potential strategy to treat oseltamivir-susceptible strains, we sought to determine whether synergy exists between oseltamivir and H84T. Treatment of MDCK cells infected with A/California/07/2009 (H1N1)pdm09, A/Perth/16/2009 (H3N2), A/Duck/MN/1525/1981 (H5N1), and B/Brisbane/60/2008 with both oseltamivir and H84T resulted in a virus yield reduction that exceeded one log
 <sub>10</sub> when compared to either individual drug alone, identifying possible synergy between oseltamivir and H84T for all four viruses tested (
 <xref rid="r21" ref-type="bibr">21</xref>) (
 <ext-link ext-link-type="uri" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1915152117/-/DCSupplemental" xlink:show="new" xmlns:xlink="http://www.w3.org/1999/xlink">
  <italic>SI Appendix</italic>, Tables S1â€“S4
 </ext-link>). We further examined the effect of the drug combination using 3D analysis (MacSynergy II) (
 <xref rid="r22" ref-type="bibr">22</xref>) and found that the combination of oseltamivir and H84T has minor but significant synergy against both A/California/07/2009 (H1N1)pdm09 and A/Perth/16/2009 (H3N2) (
 <ext-link ext-link-type="uri" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1915152117/-/DCSupplemental" xlink:show="new" xmlns:xlink="http://www.w3.org/1999/xlink">
  <italic>SI Appendix</italic>, Figs. S2 and S3
 </ext-link>). Thus, H84T shows some, but not striking, synergy with oseltamivir.
</p>
